Aimmune Therapeutics (AIMT) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Aimmune Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
May 16, 2016 4:05 PM EDTBRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for the first quarter of 2016 and provided a corporate update. The companys lead product candidate, AR101, is currently the subject of a Phase 3 clinical study, PALISADE, in peanut-allergic individuals ages 4-55 years.
We made significant progress in the first quarter of 2016 highlighted by commencing enrollment in PALISADE and reporting positive new data from our Phase 2... More
